Brain tumor research advocates, including Accelerate Brain Cancer Cure, were instrumental in the successful restoration of the program funding.
Accelerate Brain Cancer Cure was the first non-profit to fund Tocagen's virally-based drug delivery and treatment system for brain cancer.
Max Wallace, CEO of Accelerate Brain Cancer Cure, is a sought-after speaker at biotechnology conferences focusing on new approaches to funding treatments of the world’s most challenging diseases.
The BRAIN Initiative Challenges Researchers to Unlock Mysteries of Human Mind.
Ashley Varner guest blogs about her social work pilot study on the lived experience of family members who live with someone diagnosed with a primary malignant brain tumor.
In partnership with UCSF and MD Anderson, ABC2 brought together researchers from leading medical centers and biotech companies to strategize new therapeutic paths to treat Low Grade Gliomas.
The collaboration between academic and industry researchers aims to develop a test to detect genetic brain tumor mutations in cerebral spinal fluid and blood.
Max Wallace, CEO of Accelerate Brain Cancer Cure, guest blogs for The Case Foundation about our new project that could revolutionize treatment for patients.
Josh Sommer is the founder of the Chordoma Foundation. He is a good friend and we work closely with his organization on a variety of rare disease initiatives.
Anne will always be remembered for her kind smile, wonderful sense of humor and determination to make this world a better place.
Max will join a panel of R&D experts to discuss "The Evolving Research Enterprise: The Role of Foundations and Strategic Funding."
Max Wallace, CEO of Accelerate Brain Cancer Cure, provides perspective on the latest Avastin trial results by Genentech.
A Unique Opportunity To Learn About The Most Innovative New Trends In Brain Tumor Research.
A blog post from Max Wallace, CEO of Accelerate Brain Cancer Cure.
Max Wallace, CEO of Accelerate Brain Cancer Cure, is featured this week in the leading innovation economy publication, Xconomy.
The projects were selected by a review committee, which includes Max Wallace, CEO of Accelerate Brain Cancer Cure.
We are pleased to launch our Fellows program for young scientific investigators. They will examine business development and strategy issues within pharmaceutical, biotechnology, financial and philanthropic organizations.
Max Wallace, CEO of Accelerate Brain Cancer Cure, provides perspective on the latest Avastin study by Genentech.
Scientists led by Dr. Luis Parada at UT Southwestern Medical Center have identified a cancer stem cell-like treatment target against glioblastoma (GBM) - the most deadly type of brain tumor.
The study, led by Antonio Iavarone at Columbia University Medical Center, pinpoints a genetic cause of some cases of glioblastoma (GBM) -- the most lethal form of brain tumor.
The research is part of the National Institute of Health's $70 million "Tissue Chip For Drug Testing" program.
University of Wisconsin-Madison research shows new prognosis tool for deadly brain cancer.
Johns Hopkins scientists hope discovery will drive drug treatments for meningioma brain tumors
A multi-partner, $8.2 million investment will develop new glioblastoma treatments.
Overall risk is low and outweighed by the reason the child needs the CT scan in the first place.